I already have an offer on the table and will be taking over upon approval. We will need to look at some cost cutting measures so I am going to have to reduce headcount. I hate that each of you will not be employed in December. Da Man
Hi, Thinking of interviewing for a position at Medivation. Do you think if I got the job, all stocks would vest upon buyout?
comments about T.L. are not fair. He is a good guy and comes with a tract record of success at Genentech. I am guessing you must have been a slacker and were figured out by TL thus your distaste.
No one will buy out Medivation. This is a company with not much asset. Xtandi is owned by Astellas and Mefivation just receives 50% of US loyalty plus small amount from Rest of the world sales. Medivation has no right for this drug anywhere. They have no more asset. Does not make sense for any company to buy Medivation shares since there is not much to gain. Reality is no one wants to partner with a Japanese company, Astellas. MDVN stock is over inflated and should not be more than $20.00/share. Market will correct itself. Unfortunately for Medivation, Abiraterone will go generic by 2017 and their competition ARN 509 will possibly hit the market soon after. If I were you, I would not become gready. Leadership of this company reminds me of another Biotech from Seattle who destroyed a good compound and a company after getting their therapy approved in Prostate Cancer. They are gready and that will be the cause of their destruction as well.
I would worry about the previous posters spell checking software. Come on son! Have a little self respect!
No one will buy Medivation. There is simply not much value. Medivation shares are inflated. They only have single product (Xtandi). Their share of Profit is only 50% of US market only. The rest (other 50% from US) as well rest of world belongs to Astellas. For now, Xtandi is almost 1.5 yrs behind Zytiga. Remember Zytiga has two indication, Pre and Post Chemo vs only Post Chemo for Xtandi. Also, Zytiga has been in more market. No doubt Xtandi is a good drug. Reality is, they came a bit too late. They will never be a market lead. Zytiga goes generic in US by end of 2016 and thereafter most likely insurance companies will force Doctors to use generic first before using a branded and more expensive Xtandi. Although these drugs have different Mechanism of Action but they are labled for same condtion and group of pTients as well cost of health care will force physicians to use generic first. In reality that is happening already and some insurance companies asking physicians to prescribe Zytiga first ( most likely they have locked cheaper price). The challenge is, duration of response for Xtandi post Zytiga is short (2-3 month) vs 6-8 month pre Zytiga. This translates to lower sales for Xtandi. I would say, Medivation stocks are inflated and are worth maximum $20.00. And MDVN market Cap of around 1.5 billion max.
